Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Algeria | Bangladesh | Belgium | Chile | China | Colombia | Egypt | France | India | Italy | Jordan | Korea | Luxembourg | Morocco | New Zealand | Peru | Philippines | Portugal | Russia | Sri Lanka | Switzerland | Taiwan | Turkey | Ukraine | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Jiudian Pharmaceutical
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Colorectal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2017-002542-72 |
COLONPREP | P3 |
Active, not recruiting |
Colorectal Cancer |
2021-07-07 |
2025-06-28 |
Treatments |
